“Best Price” Or Better? Medicare/Medicaid Rules May Confuse Rebates
Executive Summary
CMS may need to intervene in Medicaid pharmacy reimbursement practices to ensure that the Medicare Part D program runs smoothly, Mintz Levin attorney Carolyn McElroy suggested Feb. 1 during CBI's Pharmaceutical Marketing Compliance Congress in Washington, D.C
You may also be interested in...
Part D Coverage Could Lead To Drug Price Uniformity, Pfizer Exec Says
Implementation of the Medicare Part D drug benefit could ultimately mean more uniform pricing across different market segments in the U.S., a Pfizer exec suggested Jan. 25
Part D Plans Must Report Rebates Within Six Months Under CMS Proposal
The Centers for Medicare & Medicaid Services is proposing to require that Medicare prescription drug plans report all rebates within six months of the end of the coverage year, in order to calculate payments to plan sponsors
Medicaid Directors May Seek Clarification On Rebates In Medicare Rx
The National Association of State Medicaid Directors is hoping for clarification that Medicaid rebates will be factored into "clawback" payments made by states for coverage of dual eligibles under the new Medicare drug benefit